Want to see VERA full AI Analyst Report?
Top Page
Vera Therapeutics
(NASDAQ:VERA)
Select Model
Select Model
Rating:59Neutral
Price Target:
$42.00
▼(-0.71% Downside)
Action:Reiterated
Date:07/08/26
The score is held back primarily by weak financial performance (pre-revenue, accelerating losses, and heavy cash burn) and limited valuation support (negative P/E, no dividend). Offsetting this, technical momentum is positive and recent corporate events are a major tailwind, highlighted by FDA accelerated approval and a clearer path toward potential full approval.
Positive Factors
Regulatory approval: TRUTAKNA
Accelerated FDA approval converts atacicept from a pure development asset into a commercial product, materially de-risking regulatory timing. This enables initial revenue generation, commercialization planning, and payer engagement that can sustain long-term product adoption in a defined patient population.
Negative Factors
Pre-revenue, widening losses
Despite approval, the company has a history of no product revenue and rapidly expanding losses. If commercial uptake, pricing, or reimbursement lag expectations, the firm could remain loss-making for extended periods, limiting reinvestment and pressuring capital structure over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory approval: TRUTAKNA
Accelerated FDA approval converts atacicept from a pure development asset into a commercial product, materially de-risking regulatory timing. This enables initial revenue generation, commercialization planning, and payer engagement that can sustain long-term product adoption in a defined patient population.
Read all positive factors
Vera Therapeutics (VERA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.76B
Dividend YieldN/A
Average Volume (3M)2.07M
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue GrowthN/A
EPS Growth-85.06%
CountryUS
Employees249
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.54
Shares Outstanding71,782,906
10 Day Avg. Volume2,662,821
30 Day Avg. Volume2,069,953
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)5.38
Price to Sales (P/S)0.00
P/FCF Ratio-13.46
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$82.08Price Target Upside94.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-6.19
Revenue Forecast (FY)$29.55M
Vera Therapeutics Business Overview & Revenue Model
Company Description
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is at...
How the Company Makes Money
VERA is a clinical-stage biotechnology company and, based on publicly available information, it does not have an approved commercial product generating recurring product sales. As a result, its revenue (if any) is generally expected to come from n...
Vera Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 308.00K | 0.00 | 0.00 | 0.00 | 846.00K | 0.00 |
| EBITDA | -356.59M | -291.62M | -144.42M | -92.18M | -88.91M | -32.41M |
| Net Income | -368.95M | -299.62M | -152.15M | -95.99M | -89.06M | -32.61M |
Balance Sheet | ||||||
| Total Assets | 621.74M | 734.73M | 655.68M | 175.55M | 131.44M | 83.75M |
| Cash, Cash Equivalents and Short-Term Investments | 596.76M | 714.59M | 640.85M | 160.72M | 114.65M | 79.67M |
| Total Debt | 75.03M | 77.31M | 54.64M | 53.71M | 31.29M | 4.92M |
| Total Liabilities | 122.04M | 130.21M | 78.53M | 73.86M | 54.53M | 14.16M |
| Stockholders Equity | 499.70M | 604.52M | 577.15M | 101.69M | 76.91M | 69.59M |
Cash Flow | ||||||
| Free Cash Flow | -293.81M | -241.73M | -135.65M | -92.24M | -67.66M | -23.71M |
| Operating Cash Flow | -293.20M | -241.10M | -134.68M | -92.18M | -67.60M | -23.71M |
| Investing Cash Flow | 41.15M | 194.29M | -425.03M | -39.43M | -70.55M | -4.20M |
| Financing Cash Flow | 311.31M | 308.90M | 606.67M | 133.54M | 101.93M | 53.88M |
Vera Therapeutics Technical Analysis
Negative
42.30
Price Trends
37.11
Positive
38.53
Negative
38.70
Negative
Market Momentum
1.13
Positive
46.02
Neutral
30.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VERA, the sentiment is Negative. The current price of 42.3 is above the 20-day moving average (MA) of 40.94, above the 50-day MA of 37.11, and above the 200-day MA of 38.70, indicating a neutral trend. The MACD of 1.13 indicates Positive momentum. The RSI at 46.02 is Neutral, neither overbought nor oversold. The STOCH value of 30.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VERA.
Vera Therapeutics Risk Analysis
Vera Therapeutics disclosed 86 risk factors in its most recent earnings report. Vera Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vera Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $4.28B | -23.95 | -32.55% | ― | ― | -7.28% | |
59 Neutral | $2.76B | -6.95 | -74.86% | ― | ― | -85.06% | |
52 Neutral | $2.44B | -10.79 | -67.40% | ― | ― | -5.22% | |
52 Neutral | $2.32B | -2.72 | -866.46% | ― | ― | 39.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.99B | -5.18 | -60.70% | ― | 23382.78% | 7.01% | |
49 Neutral | $991.61M | -8.84 | -11.85% | ― | 47.10% | -35.51% |
* Healthcare Sector Average
VERA
Vera Therapeutics
38.50
15.71
68.93%
VRDN
Viridian Therapeutics
18.03
1.24
7.39%
PHVS
Pharvaris
34.94
11.10
46.56%
EWTX
Edgewise Therapeutics
39.76
26.37
196.94%
JANX
Janux Therapeutics Inc
16.26
-9.82
-37.65%
BHVN
Biohaven Ltd.
15.44
1.63
11.80%
Vera Therapeutics Corporate Events
Product-Related AnnouncementsRegulatory Filings and Compliance
Vera Therapeutics gains FDA nod for TRUTAKNA launch
Positive
Jul 7, 2026
On July 7, 2026, Vera Therapeutics announced that the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA™ (atacicept-vymj) to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Vera Therapeutics Advances Atacicept Approval Path in IgA Nephropathy
Positive
Jun 2, 2026
On June 2, 2026, Vera Therapeutics, Inc. announced it had reached agreement with the U.S. Food and Drug Administration on a revised, earlier analysis plan for the ORIGIN 3 study’s eGFR endpoint to support potential full approval of atacicept...
Executive/Board ChangesShareholder Meetings
Vera Therapeutics Stockholders Back Board, Governance Proposals
Positive
May 26, 2026
On May 21, 2026, Vera Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, with 71,713,905 shares of Class A common stock entitled to vote as of the March 24, 2026 record date. Stockholders elected three Class II directors—Michae...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.